Publications
Detailed Information
The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring <i>NRG1</i> gene fusions
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Dong-Wan | - |
dc.contributor.author | Schram, Alison M. | - |
dc.contributor.author | Hollebecque, Antoine | - |
dc.contributor.author | Nishino, Kazumi | - |
dc.contributor.author | Macarulla, Teresa | - |
dc.contributor.author | Rha, Sun Young | - |
dc.contributor.author | Duruisseaux, Michael | - |
dc.contributor.author | Liu, Stephen, V | - |
dc.contributor.author | Al Hallak, Mohammed Najeeb | - |
dc.contributor.author | Umemoto, Kumiko | - |
dc.contributor.author | Wesseler, Claas | - |
dc.contributor.author | Cleary, James M. | - |
dc.contributor.author | Springfeld, Christoph | - |
dc.contributor.author | Neuzillet, Cindy | - |
dc.contributor.author | Joe, Andrew | - |
dc.contributor.author | Jauhari, Shekeab | - |
dc.contributor.author | Ford, Jim | - |
dc.contributor.author | Goto, Koichi | - |
dc.date.accessioned | 2024-03-27T06:19:16Z | - |
dc.date.available | 2024-03-27T06:19:16Z | - |
dc.date.created | 2024-03-27 | - |
dc.date.created | 2024-03-27 | - |
dc.date.issued | 2024-02 | - |
dc.identifier.citation | FUTURE ONCOLOGY | - |
dc.identifier.issn | 1479-6694 | - |
dc.identifier.uri | https://hdl.handle.net/10371/199253 | - |
dc.description.abstract | NRG1 gene fusions are rare mutations that cause cancer cells to grow. These fusions are found in many different types of cancer. Tumors with NRG1 gene fusions do not respond well to standard treatment options. Zenocutuzumab, or Zeno, is a treatment that is being tested to see if it can stop cancer that is growing because of NRG1 gene fusions. Here, we describe the reasoning for and design of an ongoing clinical trial (eNRGy) designed to study the efficacy (how well it works) and safety of Zeno in patients with cancer that has NRG1 gene fusions. The eNRGy trial is recruiting patients with cancer that has NRG1 gene fusions, including non-small-cell lung cancer, pancreatic cancer and others. Patients who join this trial will receive Zeno once every 2 weeks until their cancer grows. The main goal (primary end point) of this trial is to determine the percentage of patients whose tumors decrease in size by 30% or more. The eNRGy trial is currently enrolling patients. For more information, refer to ClinicalTrials.gov (Identifier: NCT02912949), visit https://nrg1.com/, or call 1-833-NRG-1234. | - |
dc.language | 영어 | - |
dc.publisher | FUTURE MEDICINE LTD | - |
dc.title | The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions | - |
dc.type | Article | - |
dc.identifier.doi | 10.2217/fon-2023-0824 | - |
dc.citation.journaltitle | FUTURE ONCOLOGY | - |
dc.identifier.wosid | 001161632800001 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Kim, Dong-Wan | - |
dc.type.docType | Review; Early Access | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | CD74-NRG1 FUSIONS | - |
dc.subject.keywordPlus | ANTIBODY | - |
dc.subject.keywordAuthor | eNRGy trial | - |
dc.subject.keywordAuthor | HER2 | - |
dc.subject.keywordAuthor | HER3 | - |
dc.subject.keywordAuthor | NRG1+ | - |
dc.subject.keywordAuthor | NRG1 fusion | - |
dc.subject.keywordAuthor | NSCLC | - |
dc.subject.keywordAuthor | PDAC | - |
dc.subject.keywordAuthor | recruiting | - |
dc.subject.keywordAuthor | Zeno | - |
dc.subject.keywordAuthor | Zenocutuzumab | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.